Clarinex

Clarinex is a tricyclic antihistamine, which has a selective and peripheral H1-antagonist action. It is used to treat allergies. It has a long-lasting effect and does not cause drowsiness because it does not readily enter the central nervous system.


Most likely, Clarinex - a mixture:
Clarinex-D 12 Hour Extended Release Tablets (desloratadine + pseudoephedrine)

Medicinal name:
  • 12 HR desloratadine 2.5 MG / Pseudoephedrine sulfate 120 MG Extended Release Oral Tablet [Clarinex-D]
  • Desloratadine 5 MG Oral Tablet [Clarinex]
  • Clarinex-D (desloratadine 5 MG / pseudoephedrine sulfate 240 MG) 24 HR Extended Release Tablet

Clarinex - Pharmacology:

Like other H1-blockers, Clarinex competes with free histamine for binding at H1-receptors in the GI tract, uterus, large blood vessels, and bronchial smooth muscle. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.

Clarinex mini report

Clarinex NDA
NDA - A product marketed under an approved New Drug Application
Clarinex SOLUTION
SOLUTION
Clarinex TABLET, FILM COATED
TABLET, FILM COATED
Clarinex HUMAN PRESCRIPTION DRUG
HUMAN PRESCRIPTION DRUG
Clarinex global name
Desloratadine
Clarinex global name
desloratidine
Start - Stop data
START DATA:
2004-Sep-01
Start - Stop data
STOP DATA
not occurred

Clarinex Interactions

In two controlled crossover clinical pharmacology studies in healthy male (n=12 in each study) a nd female (n=12 in each study) volunteers, desloratadine 7.5 mg (1.5 times the daily dose) once daily was coadministered with erythromycin 500 mg every 8 hours or ketoconazole 200 mg every 12 hours for 10 days. In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers. Although increased plasma concentrations (C max and AUC 0-24 hrs) of desloratadine and 3-hydroxydesloratadine were observed , there were no clinically relevant changes in the safety profile of desloratadine, as assessed by electrocardiographic parameters (including the corrected QT interval), clinical laboratory tests, vital signs, and adverse events.

Table 1
Changes in Clarinex and 3-Hydroxydesloratadine Pharmacokinetics in Healthy Male and Female Volunteers
 
Clarinex 3-Hydroxydesloratadine
 
C max AUC
0-24 hrs
C max AUC
0-24 hrs
Erythromycin
(500 mg Q8h)
+24% +14% +43% +40%
Ketoconazole
(200 mg Q12h)
+45% +39% +43% +72%
Azithromycin
(500 mg day 1,
250 mg QD × 4 days)
+15% +5% +15% +4%
Fluoxetine
(20 mg QD)
+15% +0% +17% +13%
Cimetidine
(600 mg Q12h)
+12% +19% -11%  -3%

Clarinex Contraindications

CLARINEX Tablets 5 mg are contraindicated in patients who are hypersensitive to this medication or to any of its ingredients, or to loratadine.

Manufacturers name:

  • Merck Sharp & Dohme Corp
  • Rebel Distributors Corp
  • Physicians Total Care, Inc

Generic name, Overdose, Half Life Clarinex, Food Interactions, Chemical, etc..

Clarinex see also Stinging Nettle

Brand Names containing Desloratadine
Allergy